The U.S. FDA declined to approve a pre-filled syringe version of Regeneron Pharmaceuticals Inc.’s blockbuster eye drug Eylea.
Ionis Pharmaceuticals inked a deal worth more than $700 million with pharma giant Roche to develop an antisense drug for the treatment of complement-mediated diseases.
Esperion’s Bemopedoic Acid Treatments Hit the Mark in Two Studies
"Bad" LDL Cholesterol, Atherosclerotic Cardiovascular Disease (ASCVD), Clinical Data, Clinical Studies, Clinical Trials, European Society of Cardiology (ESC) Congress, FDA, Marketing Authorization Applications, New Drug Applications, R&D, StatinsAnn Arbor, Mich.-based Esperion Therapeutics reported final results from a long-term safety study of bempedoic acid 180 mg versus placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) whose disease is inadequately controlled by statins.
Pfizer rare heart disease drug reduces risk of death by 30 percent in study
Breakthrough Therapy Status, Clinical Data, Clinical Studies, Clinical Trials, Familial Amyloid Polyneuropathy, FDA, Heart Disease, Hereditary TTR Amyloidosis (hATTR), Neurodegenerative Diseases, Potential Blockbusters, R&D, Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Pfizer Inc.’s tafamidis reduced the risk of death for patients with a rare and fatal heart disease by around 30 percent, boosting the prospects of what could be a billion-dollar-a-year drug.
BioLineRx Ltd. announced the expansion of its immuno-oncology collaboration with Merck & Co. Inc. for the support of a Phase 2a program investigating BioLineRx’s BL-8040 in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) in patients with metastatic pancreatic cancer.
AbbVie is taking another shot at solid tumor treatments through a collaboration with La Jolla, Calif.-based Calibr – a nonprofit drug discovery division of Scripps Research – to develop next-generation T-cell therapies that are aimed at targeting solid tumors.
Imbruvica Plus Gazyva Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia Patients Met Primary Endpoint
Biopharma, Bruton's Tyrosine Kinase (BTK) Inhibitors, Chronic Lymphocytic Leukemia (CLL), Clinical Studies, Progression-Free Survival (PFS), Small Lymphocytic Lymphoma (SLL)AbbVie, a research-based global biopharmaceutical company, announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival.
Clinical data suggests that uniQure’s AAV5 gene therapy may be viable treatments for 97 percent of hemophilia B patients.
General Electric is diving deeper into the world of biotechnology. The conglomeration is launching prefabricated manufacturing units to product virus-based gene and cell therapies, Reuters reported.
